Xingqi Pharmaceutical released its 2026 interim report, showing first-half net profit attributable to the parent of 430 million yuan, up 28.5% year-on-year. Operating revenue was 1.4 billion yuan, up 20.5% year-on-year; non-GAAP net profit attributable to the parent was 432 million yuan, up 30.4%; net operating cash flow was 393 million yuan, up 28.8%; earnings per share were 1.2127 yuan. In the second quarter, operating revenue was 718 million yuan, up 14.5% year-on-year, and net profit attributable to the parent was 224 million yuan, up 18.6%. As of the end of the second quarter, total assets were 2.743 billion yuan, up 8.0% from the end of the previous year, and net assets attributable to the parent were 2.163 billion yuan, up 9.4%. The company said that during the reporting period it advanced digital transformation, adopted a contract manufacturing model for some products, and made progress in research and development, including clinical trial approvals for new drugs and registration certificates.
Shenyang Xingqi Pharmaceutical Co LtdFirst-half net profit up 28.5% and revenue up 20.5% beat expectations.
